Get the Stockscreener App
4.10
6.56%
-0.32
Inozyme Pharma Inc stock is traded at $4.10, with a volume of 191.02K.
It is down -6.56% in the last 24 hours and down -20.12% over the past month.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
See More
Previous Close:
$4.42
Open:
$4.39
24h Volume:
191.02K
Relative Volume:
0.77
Market Cap:
$296.58M
Revenue:
-
Net Income/Loss:
$-71.17M
P/E Ratio:
-2.6452
EPS:
-1.55
Net Cash Flow:
$-70.97M
1W Performance:
-10.61%
1M Performance:
-20.12%
6M Performance:
-12.87%
1Y Performance:
+29.87%
1-Day Range:
$4.07
$4.455
1-Week Range:
$4.07
$4.78
52-Week Range:
$2.71
$7.795
Inozyme Pharma Inc Stock (INZY) Company Profile
Name
Inozyme Pharma Inc
Sector
Industry
Phone
857-330-4340
Address
321 SUMMER STREET, BOSTON
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Initiated | Stifel | Buy |
| Aug-13-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| Mar-23-23 | Upgrade | Jefferies | Hold → Buy |
| May-26-22 | Initiated | Jefferies | Hold |
| Feb-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-29-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Inozyme Pharma Inc Stock (INZY) Latest News
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - The Manila Times
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $16.14 - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World
Needham & Company LLC Reiterates Buy Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Inozyme reports positive trial results for kidney disease therapy - Investing.com India
Inozyme reports positive trial results for kidney disease therapy By Investing.com - Investing.com Canada
Inozyme Pharma Bullish on Treatment for End-Stage Kidney Disease - MarketWatch
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - GlobeNewswire
The Manufacturers Life Insurance Company Grows Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
(INZY) Proactive Strategies - Stock Traders Daily
Inozyme Pharma presents kidney disease study at ASN Kidney Week By Investing.com - Investing.com Nigeria
Inozyme Pharma presents kidney disease study at ASN Kidney Week - Investing.com
Inozyme Pharma Announces Presentation of Interim Data from - GlobeNewswire
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024 - Yahoo Finance
Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 6.9% - MarketBeat
Dimensional Fund Advisors LP Purchases 205,417 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Millennium Management LLC Acquires 1,084,341 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Cubist Systematic Strategies LLC Invests $84,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma appoints new board member - Investing.com
Inozyme Pharma appoints new board member By Investing.com - Investing.com South Africa
Inozyme Pharma Welcomes New Director Erik Harris - TipRanks
Inozyme appoints Erik Harris to board of directors - TipRanks
Inozyme Pharma Appoints Erik Harris to its Board of Directors - citybiz
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its - The Bakersfield Californian
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors - GlobeNewswire
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of - EIN News
How the (INZY) price action is used to our Advantage - Stock Traders Daily
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by American Century Companies Inc. - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Wedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Deerfield Management Company L.P. Series C Takes Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Blue Owl Capital Holdings LP Cuts Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Long Term Trading Analysis for (INZY) - Stock Traders Daily
Inozyme Pharma Presents New Data at the American Society - GlobeNewswire
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) - The Bakersfield Californian
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting - StockTitan
Affinity Asset Advisors LLC Acquires 213,733 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Stock Position Raised by Affinity Asset Advisors LLC - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Holdings Raised by Samlyn Capital LLC - Defense World
Samlyn Capital LLC Has $14.94 Million Stock Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Bank of New York Mellon Corp Grows Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
How to Take Advantage of moves in (INZY) - Stock Traders Daily
Stifel Nicolaus Initiates Coverage on Inozyme Pharma (NASDAQ:INZY) - Defense World
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look' - Benzinga
Inozyme Pharma (NASDAQ:INZY) Coverage Initiated at Stifel Nicolaus - MarketBeat
Inozyme stock draws buy at Stifel on lead drug (NASDAQ:INZY) - Seeking Alpha
Stifel sets $16 target on Inozyme Pharma with buy rating By Investing.com - Investing.com Australia
Stifel sets $16 target on Inozyme Pharma with buy rating - Investing.com India
Inozyme Pharma Inc Stock (INZY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):